 PROSPECTIVE, RANDOMIZED, MULTICENTRE, OPEN-LABEL, PHASE II III STUDY TO ASSESS EFFICACY AND SAFETY OF RANIBIZUMAB 0.5 MG INTRAVITREAL INJECTIONS PLUS PANRETINAL PHOTOCOAGULATION PRP VERSUS PRP IN MONOTHERAPY IN THE TREATMENT OF SUBJECTS WITH HIGH RISK PROLIFERATIVE DIABETIC RETINOPATHY.: 